‘Measuring the Economic Footprint of the Biotechnology in the European Union’ estimates the contribution of the biotechnology industry to the EU economy and labour market in terms of gross value added, productivity, employment and trade within 27 European Member States.

Direct, indirect, and induced effects generated by the biotechnology industry in the EU27 between 2008-2022 are quantified in accordance with the system of national accounts and using a multiregional input-output model.

This economic footprint analysis provides an overall economic snapshot of the EU biotechnology industry, supplemented by trade and R&D figures. It sheds light on the performance of the industry, its direct contribution to the EU’s GDP and labour market, as well as on the spillover effects into EU supply chains.

The study does not measure the substantial economic activity linked to those companies that may be pre-revenue or providing biotechnology services. It does however capture the value of many of the products that are consumed by this community during its operation, indicating the substantial innovation engine that underpins economic outputs delivered later in the value chain.

This study was commissioned by EuropaBio, the European Association of Bioindustries, with the objective to better quantify the impact of the biotechnology industry on the European Union’s economy.

For more information, contact communications@europabio.org or c.skentelbery@europabio.org.

View and download the full executive summary and the full study below.